The downsides, however, include the possible loss of target with MHC loss or down-regulation on cancer cells as noted earlier [6,12], HLA restriction and the requirement for HLA matching and the effects of a repressive tumor environment, including T cell checkpoints [275]. Here, HLA-C is linked to neoplasm.